ECSP15010550A - Preparación farmacéutica sólida que contiene levotiroxina - Google Patents

Preparación farmacéutica sólida que contiene levotiroxina

Info

Publication number
ECSP15010550A
ECSP15010550A ECIEPI201510550A ECPI201510550A ECSP15010550A EC SP15010550 A ECSP15010550 A EC SP15010550A EC IEPI201510550 A ECIEPI201510550 A EC IEPI201510550A EC PI201510550 A ECPI201510550 A EC PI201510550A EC SP15010550 A ECSP15010550 A EC SP15010550A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical preparation
solid pharmaceutical
levothyroxin
preparation containing
gelatin
Prior art date
Application number
ECIEPI201510550A
Other languages
English (en)
Inventor
Reiner Vonderschmitt
Hiltrud Lindenblatt
Thomas Frank
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46832170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP15010550(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP15010550A publication Critical patent/ECSP15010550A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una preparación farmacéutica sólida que comprende levotiroxina sódica, gelatina, ácido cítrico y un relleno. La preparación farmacéutica sólida tiene una estabilidad mejorada.
ECIEPI201510550A 2012-08-20 2015-03-19 Preparación farmacéutica sólida que contiene levotiroxina ECSP15010550A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12005960 2012-08-20

Publications (1)

Publication Number Publication Date
ECSP15010550A true ECSP15010550A (es) 2015-12-31

Family

ID=46832170

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201510550A ECSP15010550A (es) 2012-08-20 2015-03-19 Preparación farmacéutica sólida que contiene levotiroxina

Country Status (33)

Country Link
US (2) US20150231101A1 (es)
EP (1) EP2885005B1 (es)
JP (1) JP6195424B2 (es)
KR (1) KR102184254B1 (es)
CN (1) CN104582731B (es)
AR (1) AR092151A1 (es)
AU (1) AU2013304795B2 (es)
BR (1) BR112015003116B1 (es)
CA (1) CA2882372A1 (es)
CL (1) CL2015000390A1 (es)
CO (1) CO7200278A2 (es)
DK (1) DK2885005T3 (es)
EA (1) EA027189B1 (es)
EC (1) ECSP15010550A (es)
ES (1) ES2654306T3 (es)
HR (1) HRP20171784T1 (es)
HU (1) HUE035222T2 (es)
IL (1) IL237322A0 (es)
LT (1) LT2885005T (es)
MX (1) MX353618B (es)
MY (1) MY184400A (es)
NO (1) NO2885005T3 (es)
NZ (1) NZ703038A (es)
PE (1) PE20150597A1 (es)
PH (1) PH12014502856B1 (es)
PL (1) PL2885005T3 (es)
PT (1) PT2885005T (es)
RS (1) RS56745B1 (es)
SG (1) SG11201501122WA (es)
SI (1) SI2885005T1 (es)
TW (1) TWI603730B (es)
UA (1) UA115247C2 (es)
WO (1) WO2014029464A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
PL3576795T3 (pl) * 2017-02-03 2021-10-25 Berlin-Chemie Ag Doustny tarczycowy środek leczniczy
IT201800003615A1 (it) * 2018-03-15 2019-09-15 Altergon Sa Formulazioni altamente stabili di ormone tiroideo in capsule molli
US12083226B2 (en) * 2018-07-30 2024-09-10 Daiichi Sankyo Company, Limited Stabilizer-containing solid drug formulation
CN109364043A (zh) * 2018-12-10 2019-02-22 唐熠达 一种治疗甲状腺功能异常的缓控释药物组合物
CN110075305A (zh) * 2019-05-22 2019-08-02 上海葆隆生物科技有限公司 一种含有左甲状腺素钠的药物组合物
CN115737576B (zh) * 2022-11-14 2024-05-07 山东创新药物研发有限公司 一种左甲状腺素钠片剂及其制备方法
WO2024253724A1 (en) * 2023-06-07 2024-12-12 Genus Lifesciences Inc. Pharmaceutical oral solid dosage forms including liothyronine and levothyroxine salts and methods of making and using the same
CN117016785B (zh) * 2023-09-15 2025-08-29 华北制药河北华维健康产业有限公司 一种功能性叶黄素咀嚼片及其制备方法
WO2025245024A1 (en) * 2024-05-20 2025-11-27 Regents Of The University Of Minnesota Compositions comprising liothyronine and methods of making thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
GB9401879D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
DE19541128C2 (de) 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
WO1999022719A1 (fr) * 1997-10-30 1999-05-14 Morishita Jintan Co., Ltd. Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US8293272B2 (en) * 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
AU2004234176B2 (en) * 2003-05-02 2010-05-13 Globopharm Pharmazeutische Produktions- Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
IT1395454B1 (it) 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
US20110206775A1 (en) * 2010-01-27 2011-08-25 Groenewoud Pieter J Preparation of inert pharmaceutical excipients for stabilizing unstable pharmaceutical ingredients

Also Published As

Publication number Publication date
BR112015003116A2 (pt) 2017-07-04
AU2013304795A1 (en) 2015-04-02
UA115247C2 (uk) 2017-10-10
PH12014502856A1 (en) 2015-02-23
HUE035222T2 (hu) 2018-05-02
CA2882372A1 (en) 2014-02-27
CL2015000390A1 (es) 2015-07-10
JP6195424B2 (ja) 2017-09-13
US11298331B2 (en) 2022-04-12
NO2885005T3 (es) 2018-02-24
AR092151A1 (es) 2015-03-25
PL2885005T3 (pl) 2018-01-31
EA201500245A1 (ru) 2015-07-30
WO2014029464A1 (en) 2014-02-27
PT2885005T (pt) 2018-01-03
SG11201501122WA (en) 2015-03-30
CN104582731B (zh) 2020-01-10
HK1204961A1 (en) 2015-12-11
EP2885005A1 (en) 2015-06-24
BR112015003116B1 (pt) 2020-05-12
LT2885005T (lt) 2017-12-27
MX353618B (es) 2018-01-22
CO7200278A2 (es) 2015-05-29
KR20150042289A (ko) 2015-04-20
EP2885005B1 (en) 2017-09-27
US20170304246A1 (en) 2017-10-26
AU2013304795B2 (en) 2017-11-23
RS56745B1 (sr) 2018-03-30
NZ703038A (en) 2018-01-26
SI2885005T1 (en) 2018-01-31
DK2885005T3 (en) 2018-01-02
TW201412305A (zh) 2014-04-01
EA027189B1 (ru) 2017-06-30
US20150231101A1 (en) 2015-08-20
IL237322A0 (en) 2015-04-30
TWI603730B (zh) 2017-11-01
CN104582731A (zh) 2015-04-29
HRP20171784T1 (hr) 2017-12-29
MX2015001930A (es) 2015-06-22
KR102184254B1 (ko) 2020-11-30
PE20150597A1 (es) 2015-05-06
JP2015525802A (ja) 2015-09-07
ES2654306T3 (es) 2018-02-13
PH12014502856B1 (en) 2021-04-14
MY184400A (en) 2021-04-01

Similar Documents

Publication Publication Date Title
ECSP15010550A (es) Preparación farmacéutica sólida que contiene levotiroxina
JOP20180102B1 (ar) مركب صيدلاني
CY1120758T1 (el) Σταθερα στοματικα διαλυματα για συνδυασμενα εφς
BR112015014502A2 (pt) composições para higiene oral contendo haletos de zinco-aminoácidos
EA201300989A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
MX374468B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
CL2014003055A1 (es) Procedimiento para preparar una composicion farmaceutica que comprende i) proporcionar una primera combinacion que comprende un compuesto inhibidor del proteasoma peptidico, una o mas ciclodextrinas y agua, y ii) poner en contacto la primera combinacion con un acido para formar una segunda combinacion; composicion farmaceutica.
CO2017007316A2 (es) Formulación farmacéutica
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
BR112014032501A2 (pt) composto, e, composição farmacêutica.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
EA201990093A1 (ru) Двухкомпонентная композиция
EA201690395A1 (ru) Стабильная фармацевтическая композиция, содержащая бисопролол и рамиприл
EA201690216A1 (ru) Фармацевтические композиции ранолазина и дронедарона
EA201890477A1 (ru) Инкапсулированная композиция финголимода
EA201591644A1 (ru) Лекарственная форма, содержащая кризотиниб
UY34769A (es) Forma farmacéutica oral para la prevención de enfermedades vasculares, comprimido como forma farmacéutica y cápsula gelatinosa como forma farmacéutica
TR201104864A2 (tr) Deksketoprofen içeren suda çözünebilir formülasyonlar.
TR201203404A2 (tr) Alfa lipoik asit ve B vitamini içeren kombinasyon.
CO7141421A2 (es) Formulación farmacéutica que tiene estabilidad mejorada
TH1401003407A (th) การปรับปรุงให้ดีขึ้นใน หรือ ความสัมพันธ์กับการห่อหุ้มแคปซูลของน้ำหอม